【ST普利：未与美国GPO Premier, Inc.签订相关协议】ST普利公告，公司未与美国GPO Premier, Inc.签订任何形式的相关协议。SLATE RUN PHARMACEUTICALS，LLC与美国GPO Premier, Inc.签订造影剂合作协议，双方尚未明确约定销售数量等具体的销售安排。公司造影剂相关产品销售规模和毛利率存在较大的不确定性，对公司业绩影响也存在着不确定性。公司2021年、2022年年度报告存在虚假记载，虚假记载的营业收入金额合计达10.31亿元，且占该2年披露的年度营业收入合计金额的31.08%；虚假记载的利润总额金额合计达6.95亿元，且占该2年披露的年度利润总额合计金额的76.72%。公司股票可能被实施重大违法强制退市。

金融界

Yesterday

*ST普利公告，公司未与美国GPO Premier, Inc.签订任何形式的相关协议。SLATE RUN PHARMACEUTICALS，LLC与美国GPO Premier, Inc.签订造影剂合作协议，双方尚未明确约定销售数量等具体的销售安排。公司造影剂相关产品销售规模和毛利率存在较大的不确定性，对公司业绩影响也存在着不确定性。公司2021年、2022年年度报告存在虚假记载，虚假记载的营业收入金额合计达10.31亿元，且占该2年披露的年度营业收入合计金额的31.08%；虚假记载的利润总额金额合计达6.95亿元，且占该2年披露的年度利润总额合计金额的76.72%。公司股票可能被实施重大违法强制退市。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2517171829"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2517171829\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2517171829?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-03-05 22:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517171829","market":"hk","top_or_hot":-1,"title":"【*ST普利：未与美国GPO Premier, Inc.签订相关协议】*ST普利公告，公司未与美国GPO Premier, Inc.签订任何形式的相关协议。SLATE RUN PHARMACEUTICALS，LLC与美国GPO Premier, Inc.签订造影剂合作协议，双方尚未明确约定销售数量等具体的销售安排。公司造影剂相关产品销售规模和毛利率存在较大的不确定性，对公司业绩影响也存在着不确定性。公司2021年、2022年年度报告存在虚假记载，虚假记载的营业收入金额合计达10.31亿元，且占该2年披露的年度营业收入合计金额的31.08%；虚假记载的利润总额金额合计达6.95亿元，且占该2年披露的年度利润总额合计金额的76.72%。公司股票可能被实施重大违法强制退市。","media":"金融界","content":"<html><body><div><span><a href=\"https://laohu8.com/S/300630\">*ST普利</a></span>公告，公司未与美国GPO Premier, Inc.签订任何形式的相关协议。SLATE RUN PHARMACEUTICALS，LLC与美国GPO Premier, Inc.签订造影剂合作协议，双方尚未明确约定销售数量等具体的销售安排。公司造影剂相关产品销售规模和毛利率存在较大的不确定性，对公司业绩影响也存在着不确定性。公司2021年、2022年年度报告存在虚假记载，虚假记载的营业收入金额合计达10.31亿元，且占该2年披露的年度营业收入合计金额的31.08%；虚假记载的利润总额金额合计达6.95亿元，且占该2年披露的年度利润总额合计金额的76.72%。公司股票可能被实施重大违法强制退市。</div></body></html>","source":"jinrongjie_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>【*ST普利：未与美国GPO Premier, Inc.签订相关协议】*ST普利公告，公司未与美国GPO Premier, Inc.签订任何形式的相关协议。SLATE RUN PHARMACEUTICALS，LLC与美国GPO Premier, Inc.签订造影剂合作协议，双方尚未明确约定销售数量等具体的销售安排。公司造影剂相关产品销售规模和毛利率存在较大的不确定性，对公司业绩影响也存在着不确定性。公司2021年、2022年年度报告存在虚假记载，虚假记载的营业收入金额合计达10.31亿元，且占该2年披露的年度营业收入合计金额的31.08%；虚假记载的利润总额金额合计达6.95亿元，且占该2年披露的年度利润总额合计金额的76.72%。公司股票可能被实施重大违法强制退市。</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【*ST普利：未与美国GPO Premier, Inc.签订相关协议】*ST普利公告，公司未与美国GPO Premier, Inc.签订任何形式的相关协议。SLATE RUN PHARMACEUTICALS，LLC与美国GPO Premier, Inc.签订造影剂合作协议，双方尚未明确约定销售数量等具体的销售安排。公司造影剂相关产品销售规模和毛利率存在较大的不确定性，对公司业绩影响也存在着不确定性。公司2021年、2022年年度报告存在虚假记载，虚假记载的营业收入金额合计达10.31亿元，且占该2年披露的年度营业收入合计金额的31.08%；虚假记载的利润总额金额合计达6.95亿元，且占该2年披露的年度利润总额合计金额的76.72%。公司股票可能被实施重大违法强制退市。\n</h2>\n<h4 class=\"meta\">\n\n\n2025-03-05 22:03 北京时间   <a href=\"https://24h.jrj.com.cn/2025/03/05220348547640.shtml\"><strong>金融界</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>*ST普利公告，公司未与美国GPO Premier, Inc.签订任何形式的相关协议。SLATE RUN PHARMACEUTICALS，LLC与美国GPO Premier, Inc.签订造影剂合作协议，双方尚未明确约定销售数量等具体的销售安排。公司造影剂相关产品销售规模和毛利率存在较大的不确定性，对公司业绩影响也存在着不确定性。公司2021年、2022年年度报告存在虚假记载，虚假记载的营业收入...</p>\n<a href=\"https://24h.jrj.com.cn/2025/03/05220348547640.shtml\">Source Link</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RUN","symbol_name":"Sunrun Inc.","start_time":0,"source_url":"https://24h.jrj.com.cn/2025/03/05220348547640.shtml","article_id":"2517171829","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517171829","pubTimestamp":1741183436,"columns":[],"sourceInfo":{"source_id":"jinrongjie_stock","name":"金融界"},"weMediaInfo":null,"summary":"SLATE RUN PHARMACEUTICALS，LLC与美国GPO Premier, Inc.签订造影剂合作协议，双方尚未明确约定销售数量等具体的销售安排。公司造影剂相关产品销售规模和毛利率存在较大的不确定性，对公司业绩影响也存在着不确定性。公司2021年、2022年年度报告存在虚假记载，虚假记载的营业收入金额合计达10.31亿元，且占该2年披露的年度营业收入合计金额的31.08%；虚假记载的利润总额金额合计达6.95亿元，且占该2年披露的年度利润总额合计金额的76.72%。公司股票可能被实施重大违法强制退市。","collect":0,"end_time":0,"defaultTopTitle":"jrj.com.cn","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"300630":"*ST普利","RUN":"Sunrun Inc."},"translate_title":"[* ST Puli: No relevant agreement has been signed with GPO Premier, Inc. of the United States] * ST Puli announced that the company has not signed any relevant agreement with GPO Premier, Inc. of the United States. SLATE RUN PHARMACEUTICALS, LLC signed a contrast agent cooperation agreement with GPO Premier, Inc. of the United States. The two parties have not clearly agreed on specific sales arrangements such as sales quantity. There is great uncertainty in the sales scale and gross profit margin of the company's contrast agent-related products, and there is also uncertainty in the impact on t","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300630":1,"RUN":1},"content_text":"*ST普利公告，公司未与美国GPO Premier, Inc.签订任何形式的相关协议。SLATE RUN PHARMACEUTICALS，LLC与美国GPO Premier, Inc.签订造影剂合作协议，双方尚未明确约定销售数量等具体的销售安排。公司造影剂相关产品销售规模和毛利率存在较大的不确定性，对公司业绩影响也存在着不确定性。公司2021年、2022年年度报告存在虚假记载，虚假记载的营业收入金额合计达10.31亿元，且占该2年披露的年度营业收入合计金额的31.08%；虚假记载的利润总额金额合计达6.95亿元，且占该2年披露的年度利润总额合计金额的76.72%。公司股票可能被实施重大违法强制退市。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0}}}